Brown University

Renowned Brown University physician-scientist Eric M. Morrow, MD, PhD, to lead trailblazing initiative focused on accelerating discovery and improving care across the lifespan PHILADELPHIA, April 29, 2026 /PRNewswire/ -- Penn Medicine and Children's Hospital of Philadelphia (CHOP) today announced the appointment of Eric M. Morrow, MD, PhD, as the founding director of the Lurie Autism Institute. Dr. Morrow will assume this role on September 1, 2026, and will join the departments of Pediatrics and Genetics at the Perelman School of Medicine (PSOM) at the University of Pennsylvania. Continue Reading Dr. Eric Morrow The appointment marks a pivotal milestone for the Lurie Autism Institute, launched by a transformational, $50 million gift from Jeffrey Lurie Family Foundation and the Nancy Lurie Marks Family Foundation in 2025. It is the largest single donation to a U.S. academic medical center focused on autism research across the lifespan. The institute will serve as a nationally and globally recognized hub for autism spectrum disorder research, collaboration, clinical care, and advocacy. The institute's headquarters and research laboratories will be located on Children's Hospital of Philadelphia's campus, spanning adjacent buildings to facilitate close collaboration and discovery between Penn Medicine and CHOP. "We are thrilled to welcome Dr. Morrow to lead this once-in-a-generation initiative," said Jonathan A. Epstein, dean of the Perelman School of Medicine and executive vice president of the University of Pennsylvania for the Health System. "His extraordinary depth of scientific and clinical expertise in autism and related neurodevelopmental disorders, combined with his collaborative approach and longstanding ties to both Penn and CHOP, position him to drive the kind of cross-disciplinary discovery that this moment demands." "At Children's Hospital of Philadelphia, we see firsthand how autism affects children and families," said Madeline Bell, chief executive officer of Children's Hospital of Philadelphia. "Dr. Morrow is an extraordinary scientist who is committed to translating research into life-changing breakthroughs in care. Under his leadership, the Lurie Autism Institute will focus on finding innovative ways to deliver better care and outcomes for patients throughout their lives." Following a highly competitive national search that attracted outstanding candidates across the country, Dr. Morrow emerged as the primary choice. His extensive knowledge of autism spectrum disorder, rigorous research program, and longstanding research collaboration with Penn Medicine and CHOP distinguished him as a visionary leader for the institute's ambitious mission. "From the very beginning, our family's vision for the Lurie Autism Institute has been to create something truly transformational for the millions of families touched by autism around the world," said Jeffrey Lurie, chairman and CEO of the Philadelphia Eagles and founder of the Eagles Autism Foundation. "Dr. Morrow is exactly the kind of bold, rigorous, and compassionate leader this institute requires. His decades of scientific achievement, deep commitment to the autism community, and belief in the power of partnership give us tremendous confidence that the institute will make life-changing discoveries. We are so excited to continue this journey together." A Distinguished Physician-Scientist Dr. Morrow currently serves as the Mencoff Family Professor in the departments of molecular biology, cell biology and biochemistry, neuroscience, and psychiatry at Brown University. He also serves as director of the Center for Translational Neuroscience and director of the Developmental Disorders Genetics Research Program at Emma Pendleton Bradley Hospital. He earned his PhD in genetics and neurodevelopment from Harvard University and his MD through the Health Science Training Program at the Massachusetts Institute of Technology and Harvard Medical School. He completed clinical and scientific training in neurology and psychiatry at Harvard Medical School. Dr. Morrow's laboratory is a global leader in translational neurogenetics. His research focuses on the molecular mechanisms and genetic underpinnings of neurodevelopmental disorders, including autism and intellectual disability. His laboratory investigates the tiny structures inside brain cells that handle critical jobs like generating energy and clearing out cellular waste. When these structures stop working properly, neurons can be damaged or even die off over time. Dr. Morrow's lab has made important strides in understanding rare inherited conditions – including Christianson syndrome and GPT2 deficiency – shedding light on why certain brain cells are more vulnerable to deterioration than others. Building on these discoveries, his work focuses on developing treatments that target the underlying biological causes of these disorders. Deep Ties to Penn Medicine, CHOP, and the Autism Research Community Dr. Morrow brings both scientific excellence and a well-established relationship with both institutions. In 2023, he served on both CHOP's and Penn Medicine's Autism External Scientific Advisory Boards. That experience deepened his understanding of the partnership between the two organizations and reinforced his view that Penn Medicine and CHOP are uniquely positioned to accelerate progress. For seven years, he has also served on the Eagles Autism Foundation's scientific review panel, helping guide a competitive process of evaluating research and funding priorities for one of the nation's leading autism-focused philanthropic organizations with international reach. "I am deeply honored to join Penn Medicine and CHOP in building the Lurie Autism Institute," said Dr. Morrow. "We are at an unprecedented moment in autism research. The convergence of genomic science, artificial intelligence, and institutional collaboration creates extraordinary opportunities to close knowledge gaps and develop therapies that can change lives. I look forward to working alongside the faculty, clinicians, trainees, families, and community members who make this partnership so strong." A Pivotal Moment for Autism Research The urgency driving the Lurie Autism Institute reflects several converging forces in science and medicine. Advances in human genome sequencing and behavioral measurement, the integration of large-scale datasets through artificial intelligence and machine learning, and new approaches to therapeutic development are quickly reshaping autism research. At the same time, work in the field has historically been fragmented across disciplines, slowing progress and contribution to a lack of approved therapies for core symptoms. The institute is designed to unite these efforts, build on decades of groundwork from the Nancy Lurie Marks Family Foundation and the Eagles Autism Foundation, and create a global hub for discovery and clinical advancement. Penn Medicine and CHOP's combined expertise and close collaboration position the institute to accelerate the journey from discovery to care. Dr. Morrow will attend the inaugural Lurie Autism Institute Annual Symposium on May 7, 2026, which convenes thought leaders in autism research to advance understanding of autism as a biologically and clinically heterogeneous condition across the lifespan. A Note of Gratitude Penn Medicine and CHOP extend their gratitude to Daniel Rader, MD, Seymour Gray Professor of Molecular Medicine, chief, division of translational and human genetics in the department of Medicine, and chair, department of Genetics at the Perelman School of Medicine, who played an instrumental role in establishing the Lurie Autism Institute and provided steady leadership as its interim director. About the Lurie Autism Institute The Lurie Autism Institute is a partnership between the Perelman School of Medicine at the University of Pennsylvania and Children's Hospital of Philadelphia, established through a $50 million gift from the Lurie Family. The Lurie Autism Institute is dedicated to driving discovery, shaping therapeutic development, and fostering partnerships with scientists, clinicians, families, students, and the broader community to improve the lives of all those living with autism spectrum disorder. Learn more at . About Penn Medicine Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System (UPHS) and Penn's Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation's first medical school. The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $580 million awarded in the 2023 fiscal year. Home to a proud history of "firsts," Penn Medicine teams have pioneered discoveries that have shaped modern medicine, including CAR T cell therapy for cancer and the Nobel Prize-winning mRNA technology used in COVID-19 vaccines. The University of Pennsylvania Health System cares for patients in facilities and their homes stretching from the Susquehanna River in Pennsylvania to the New Jersey shore. UPHS facilities include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Doylestown Health, Lancaster General Health, Princeton Health, and Pennsylvania Hospital—the nation's first hospital, chartered in 1751. Additional facilities and enterprises include Penn Medicine at Home, GSPP Rehabilitation, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others. Penn Medicine is an $11.9 billion enterprise powered by nearly 49,000 talented faculty and staff. About Children's Hospital of Philadelphia A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey. CHOP also operates the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia, the Behavioral Health and Crisis Center (including a 24/7 Crisis Response Center) and the Center for Advanced Behavioral Healthcare, a mental health outpatient facility. Its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit . Media Contacts: Kaitlyn Dvorin Children's Hospital of Philadelphia 610-618-0542 (cell) [email protected] Carol Berman Penn Medicine 267-254-8643 (cell) [email protected] Anthony Bonagura Philadelphia Eagles [email protected] SOURCE Children's Hospital of Philadelphia 21% more press release views with Request a Demo

Beyond ddPCR for Gene Therapy: The Tessie™ system enables simultaneous capsid and transgene quantitation on a single chip in the same run, supporting accurate full, partial, and empty capsid characterization, potency assessment, and regulatory-relevant AAV quality control. BOSTON, April 29, 2026 /PRNewswire/ -- NanoMosaic, Inc., a leader in advanced analytical technologies for cell and gene therapy development and manufacturing, today announced its strong scientific and commercial presence at the American Society of Gene & Cell Therapy Annual Meeting, taking place May 11-15, 2026, in Boston, Massachusetts. NanoMosaic will highlight the capabilities of its Tessie™ system, the company's flagship nanoneedle-based analytical platform and the only FDA/CBER Advanced Manufacturing Technology-designated technology for multiplex testing of vector genome and capsid titers in AAV gene therapy manufacturing. The Tessie system enables simultaneous, high-throughput quantitation of capsid and transgene on a single chip in the same run, helping developers directly assess critical AAV quality attributes in one integrated workflow. By measuring capsid and genome-related attributes together, Tessie is designed to reduce assay-to-assay bias, distinguish partials from full capsids, and provide a more accurate assessment of the true full-to-empty and full-to-partial ratio. The platform can also support potency-related assays, giving gene therapy developers and manufacturers deeper insight into product quality, process performance, batch consistency, and release-readiness. "ASGCT is the ideal venue to highlight how far the field has come, and how much more analytical precision is now required to advance gene therapies safely, efficiently, and with confidence," said John Boyce, Chief Executive Officer of NanoMosaic. "With Tessie, developers can measure capsid and transgene on one chip, at the same time, helping eliminate the bias that can occur when critical quality attributes are measured separately. This provides a clearer picture of true product composition, including partials versus fulls, and gives developers the regulatory-relevant data they need to move faster." NanoMosaic's platform recently received FDA/CBER Advanced Manufacturing Technology (AMT) designation for multiplex testing of vector genome and capsid titers in AAV gene therapy manufacturing. Through the AMT designation program, gene therapy developers implementing NanoMosaic's platform will gain access to enhanced FDA engagement, prioritized regulatory interactions, and expedited IND and BLA review pathways. At ASGCT, NanoMosaic will be featured across five scientific posters, including three customer-led posters and two NanoMosaic-authored posters, as well as one oral presentation to highlight its recent AMT designation and the significant advantages it offers developers in streamlining gene therapy development and manufacturing. NanoMosaic ASGCT 2026 Presentations Posters: Catalent: Poster No. 2212 Title: Enhancing AAV empty/full ratio accuracy: Utilizing molecular specificity to differentiate full-length from truncated transgenes Date/Time: 5/13/2026, 5:00PM-6:30PM Brown University: Poster No. 1221 Title: Overcoming an analytical bottleneck in gene therapy: a rapid and precise nanoneedle immunoassay method for detection and quantification of adeno-associated virus capsid and transgene titer Date/Time: 5/12/2026, 5:00PM-6:30PM] UMass Chan Medical School,: Poster No. 3220 Title: Improving AAV quality assessment using nanoneedle assays for full-length genome and capsid quantification Date/Time: 5/14/2026, 5:00PM-6:30PM NanoMosaic Poster 1 launching the RNA quantification assay on Tessie system: Poster No. 3222 Title: Integrated AAV genome integrity and transgene RNA quantification using a single nanoneedle-based platform Date/Time: 5/14/2026, 5:00PM-6:30PM NanoMosaic Poster 2 showcasing automated workflow on Tecan Veya platform: Poster No. 3154 Title: Automated nanoneedle assay workflow on Tecan Veya multiomics platform for scalable AAV manufacturing quality control Date/Time: 5/14/2026, 5:00PM-6:30PM Oral Presentation: Speaker: Qimin Quan, PhD., Co-Founder and Chief Scientific Officer, NanoMosaic Title: Accelerating AAV development with an FDA/CBER AMT-designated nanoneedle analytics platform Session: Analytics & Assays: New tech Date/Time: 5/14/2026, 9:30AM Location: MCEC Room 206AB "Gene therapy manufacturing has relied on proxy measurements to infer the genome integrity inside the capsid," said Qimin Quan, PhD, Co-Founder and Chief Scientific Officer of NanoMosaic. "Tessie eliminates the ambiguity of these surrogate methods by enabling direct molecular-level quantification of AAV full-length and partial transgenes, as well as capsids. By delivering these insights across the entire workflow – from crude samples in the upstream development to final release testing – we are ensuring a faster, more reliable path to clinic." Conference attendees are invited to visit NanoMosaic at Booth No.1732 to meet the team and learn how the Tessie system can help advance AAV analytics, reduce regulatory uncertainty, and support expedited development pathways through NanoMosaic's FDA/CBER AMT designation. About NanoMosaic NanoMosaic Inc. is a pioneering biotechnology company developing innovative tools and technologies for multiomic biomarker detection and analysis. The company's flagship product, the NanoMosaic Tessie™ system, is a high-throughput platform for biomarker detection that enables researchers to analyze multiple samples simultaneously with high sensitivity and specificity across proteins and nucleic acids on the same run. The system is designed to provide novel Critical Quality Attributes for cell and gene therapy development and manufacturing and to accelerate the discovery and development of biomarkers across a wide range of applications, including disease diagnosis, drug discovery, and precision medicine. Media Contact: Paul Berning NanoMosaic, Inc [email protected] +1-319-480-9464 SOURCE NanoMosaic 21% more press release views with Request a Demo

CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, May 7, 2026 at 2:00 PM ET featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center), who will join company management to discuss how bezisterim’s mechanism of action could potentially address the pathology and progression of neurodegenerative diseases, including Parkinson’s disease. To register, click here . The event will provide an update on BioVie's Phase 2 trial evaluating bezisterim (NE3107), an investigational drug candidate, for the treatment of Parkinson's disease. Bezisterim is a novel, orally-administered small molecule that, in preclinical and early clinical studies, has demonstrated potential to reduce insulin resistance and selectively inhibit inflammation-driven ERK- and NF-κB-stimulated inflammatory mediators without inhibiting their homeostatic functions. Inflammation and the associated insulin resistance contribute significantly to the development and progression of Parkinson's symptoms. A live question and answer session will follow the formal presentations. About Suzanne de la Monte, MD, MPH Suzanne de la Monte, MD, MPH is Professor in Pathology and Laboratory Medicine, Neurology, & Neurosurgery at the Warren Alpert Medical School of Brown University and Chief of Pathology & Laboratory Medicine at the Providence VA Medical Center. Dr. de la Monte is also a medical staff member at the Rhode Island Hospital and Women and Infants Hospital of Rhode Island and formerly a research fellow at the National Institutes of Health. She received residency training in Anatomic and Pediatric Pathology at Johns Hopkins and fellowship training in Neuropathology at the Massachusetts General Hospital (MGH). Dr. de la Monte leads programs in basic, translational, and clinical research on mechanisms and consequences of brain insulin resistance and metabolic dysfunction and coined the term ‘Type 3 Diabetes’. She has over 300 peer-reviewed articles published. About Bezisterim Bezisterim (NE3107) is an investigational oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNF-α), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease, Long COVID, and Alzheimer’s disease. In Parkinson’s disease, BioVie has completed a Phase 2 study in which patients with moderate- to severe stage Parkinson’s disease taking bezisterim with levodopa had better motor control and reported fewer morning symptoms compared to those taking levodopa alone. Few drug-related side effects were observed. The current SUNRISE-PD is evaluating whether bezisterim alone can help improve motor and non-motor symptoms in Parkinson’s patients who have not been treated with carbidopa/levodopa. Topline results are expected in mid-2026. For Long COVID, the ADDRESS-LC trial is enrolling about 200 patients to evaluate whether bezisterim may help reduce brain fog, fatigue, and other lingering neurological symptoms associated with Long COVID. The hypotheses being studied is that these symptoms may be triggered by persistent circulation of spike protein fragments that trigger inflammation via NFκB activation (which bezisterim has been shown to modulate). Topline data is expected mid-2026. In Alzheimer’s disease, BioVie has conducted both Phase 2 and Phase 3 trials. Preliminary data from these trials suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with Alzheimer’s. About BioVie Inc. BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead investigational drug candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for Long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue. In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit . Forward-Looking Statements This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate," "intend," "plan," "believe," "seek," "estimate," "will," "project," “potential,” “may,” or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to risk related to the early stage of development of bezisterim and other product candidates the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, the possibility that clinical trial results may not be indicative of results in subsequent or larger tirals, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. For Investor Relations Inquiries: Contact: Chuck Padala Managing Director, LifeSci Advisors, LLC chuck@lifesciadvisors.com For Media Inquiries: Contact: Melyssa Weible Managing Partner, Elixir Health Public Relations mweible@elixirhealthpr.com